PCA
DAWN

Pallas Capital Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History

Pallas Capital Advisors’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,005
Closed -$87.3K – 885
2025
Q1 		$87.3K Buy
+11,005
New +$119K ﹤0.01% 711

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pallas Capital Advisors's DAWN Position: Q2 2025 in Review

Pallas Capital Advisors sold out of Day One Biopharmaceuticals (DAWN) in Q2 2025, closing a stake of 11,005 shares — an estimated $87.3K sold.

Pallas Capital Advisors first reported a position in DAWN in Q1 2025 and held it in 1 quarter. The position peaked at $87.3K in Q1 2025. 174 funds tracked by Wall St. Rank hold DAWN as of Q2 2025.

  • Pallas Capital Advisors reported no remaining Day One Biopharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Pallas Capital Advisors sold 11,005 Day One Biopharmaceuticals shares in Q2 2025, an estimated $87.3K.
  • Pallas Capital Advisors first reported a position in Day One Biopharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Pallas Capital Advisors's Day One Biopharmaceuticals position peaked at $87.3K in Q1 2025.
  • 174 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2025.

Based on Pallas Capital Advisors's 13F filing for Q2 2025, filed 9 Jul 2025.